Kura Oncology (NASDAQ:KURA) Announces Earnings Results, Misses Estimates By $0.28 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28), Zacks reports. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million.

Kura Oncology Trading Down 0.3%

NASDAQ KURA traded down $0.03 during trading hours on Wednesday, hitting $9.94. 910,876 shares of the company’s stock were exchanged, compared to its average volume of 1,557,241. The business’s 50 day moving average is $9.08 and its 200-day moving average is $7.26. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $19.73. The firm has a market capitalization of $862.36 million, a P/E ratio of -4.41 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16.

Analysts Set New Price Targets

KURA has been the topic of several research reports. Guggenheim initiated coverage on Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating on the stock. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Zacks Research lowered Kura Oncology from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 7th. JMP Securities reissued a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Insider Buying and Selling

In other news, COO Kathleen Ford sold 6,892 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $61,614.48. Following the transaction, the chief operating officer directly owned 63,375 shares in the company, valued at $566,572.50. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Teresa Brophy Bair sold 8,805 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares of the company’s stock, valued at approximately $1,323,504.42. This trade represents a 5.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 78,058 shares of company stock worth $697,839. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in shares of Kura Oncology by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock valued at $175,000 after buying an additional 2,976 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares in the last quarter. Engineers Gate Manager LP grew its stake in Kura Oncology by 8.7% during the 2nd quarter. Engineers Gate Manager LP now owns 62,564 shares of the company’s stock valued at $361,000 after purchasing an additional 5,028 shares in the last quarter. Jump Financial LLC grew its stake in Kura Oncology by 5.0% during the 2nd quarter. Jump Financial LLC now owns 202,330 shares of the company’s stock valued at $1,167,000 after purchasing an additional 9,619 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.